Keyphrases
Sulfonylurea
100%
Dipeptidyl peptidase-4 (DPP-4)
100%
Glycemic Control
50%
Type 2 Diabetes Mellitus (T2DM)
33%
Weight Gain
33%
Pharmacotherapy
16%
Hypoglycemia Risk
16%
Safety Trial
16%
Hypoglycemia
16%
Oral Antidiabetic Drugs
16%
Adverse Effects
16%
Progressive Disease
16%
Treatment Algorithm
16%
Metformin Monotherapy
16%
Second-line Agents
16%
Drug Class
16%
Cardiovascular Risk
16%
Metformin
16%
Medicine and Dentistry
Sulfonylurea
100%
Dipeptidyl Peptidase-4 Inhibitor
100%
Glycemic Control
50%
Hypoglycemia
33%
Side Effect
33%
Type 2 Diabetes
33%
Glycon
33%
Drug Therapy
16%
Maturity Onset Diabetes of the Young
16%
Progressive Disease
16%
Monotherapy
16%
Oral Antidiabetic Agent
16%
Cardiovascular Risk
16%
Nursing and Health Professions
Dipeptidyl Peptidase IV Inhibitor
100%
Sulfonylurea
100%
Side Effect
33%
Hypoglycemia
33%
Metformin
33%
Cardiovascular Risk
16%
Drug Therapy
16%
Diseases
16%
Non Insulin Dependent Diabetes Mellitus
16%
Monotherapy
16%
Oral Antidiabetic Agent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Sulfonylurea
100%
Dipeptidyl Peptidase IV Inhibitor
100%
Hypoglycemia
33%
Side Effect
33%
Metformin
33%
Cardiovascular Risk
16%
Diseases
16%
Non Insulin Dependent Diabetes Mellitus
16%
Monotherapy
16%
Oral Antidiabetic Agent
16%
Pharmacotherapy
16%